Daewoong Pharmaceutical Co., Ltd.: Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine

Elucidated molecular mechanism behind safety and efficacy of BersiporocinBersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary FibrosisSEOUL, South Korea, May 25, 2023

Related Keywords

South Korea ,United States ,Seoul ,Soult Ukpyolsi ,Korea ,South Korean ,Jeon Sengho ,Gewinn Nur ,Lee Chang Jae ,Daewoong Bersiporocin ,Kwang Yeon Hwang ,Sunghoon Kim ,Drug Discovery Center ,School Of Pharmacy ,School Of Medicine ,Co Ltd ,Sunghoon Kim Yonsei University ,Korea University ,Korea Drug Development Fund ,Yonsei University ,Daewoong Pharmaceutical Co Ltd ,Idiopathic Pulmonary ,Asymmetric Inhibition ,Science Citation Index Expanded ,Seok Park ,Drug Designation ,Fast Track Designation ,Daewoong Pharmaceutical ,Daewoong ,Harmaceutical ,Ublishes ,Olecular ,Mechanism ,Ersiporocin ,Ntifibrotic ,Mambo ,Medicine ,